(THTX) –
-
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
-
Form 6-K Theratechnologies Inc. For: Apr 15
-
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Form 6-K Theratechnologies Inc. For: Apr 10
-
Form 6-K Theratechnologies Inc. For: Apr 10
-
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
-
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
-
Form 6-K Theratechnologies Inc. For: Apr 05
-
Theratechnologies (THTX) Appoints Elina Tea to its Board
-
Theratechnologies Appoints Elina Tea to its Board of Directors
-
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
-
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
-
Form 6-K Theratechnologies Inc. For: Mar 22
-
Form 6-K Theratechnologies Inc. For: Mar 22
-
Theratechnologies (THTX) Issues Update on Preclinical Oncology Research Program
-
Theratechnologies Announces Update on its Preclinical Oncology Research Program
-
Theratechnologies (THTX) Appoints Jordan Zwick to its Board
-
Theratechnologies Appoints Jordan Zwick to its Board of Directors
-
Form 6-K Theratechnologies Inc. For: Mar 21
-
Theratechnologies (THTX) Initiates Increased Dose Level in Phase 1 Trial of Sudocetaxel Zendusortide
-
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
Form 6-K Theratechnologies Inc. For: Feb 29
-
Theratechnologies (THTX) Announces Resignation of Alain Trudeau from Board
-
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
-
Form 6-K Theratechnologies Inc. For: Feb 27
-
Theratechnologies (THTX) Receives Refusal to File Letter for Trogarzo
-
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
-
Theratechnologies Inc. (THTX) PT Lowered to $5 at Canaccord Genuity
-
Form 20-F Theratechnologies Inc. For: Nov 30
-
Form 6-K Theratechnologies Inc. For: Feb 21
-
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
-
Theratechnologies (THTX) Reports Publication that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
-
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
-
Form 6-K Theratechnologies Inc. For: Feb 15
-
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
Form SC 13G Theratechnologies Inc. Filed by: Nantahala Capital Management, LLC
-
Form SC 13G/A Theratechnologies Inc. Filed by: HIRSCHMAN ORIN
-
Form 6-K Theratechnologies Inc. For: Feb 06
-
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
Form 6-K Theratechnologies Inc. For: Feb 01
-
Form 6-K Theratechnologies Inc. For: Jan 24
-
Theratechnologies (THTX) Receives CRL from the FDA for the F8 Formulation of Tesamorelin sBLA
-
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
-
Theratechnologies (THTX) Halted, News Pending
-
Form 6-K Theratechnologies Inc. For: Jan 23
-
Theratechnologies (THTX) Receives Update from FDA on Tesamorelin F8 Supplemental BLA
-
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
-
Form EFFECT Theratechnologies Inc.
-
Form F-3/A Theratechnologies Inc.
Back to THTX Stock Lookup
